ALKS News & Analysis
2 articles
Market Mood
Alkermes (ALKS) Quarterly Loss Narrows, Beat Analysts' Estimates
Alkermes (ALKS) reported a narrower quarterly loss, which was below analysts' expectations. The company's performance surpassed estimates, indicating potential improvement in financial health. This positive result may influence investor confidence moving forward. Specific figures of the loss and estimates were not provided in the article.
Read More
Alkermes (ALKS) Stock Price Target Raised to $53 by Mizuho
Mizuho increased its price target for Alkermes (ALKS) to $53, attributing the change to improved confidence in the company's drug pipeline. This revision reflects optimism regarding potential therapeutic advancements. The adjustment is significant for investors monitoring ALKS, as price targets can influence market sentiment and trading decisions. Increased confidence in drug development may correlate with higher stock valuations moving forward.
Read More